Jubilant Pharmova Ltd

Jubilant Pharmova Business Update

Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.

Value

₹87.31 Cr

Jubilant Pharmova Legal & Regulatory

Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.

Value

₹105.5 Cr

Jubilant Pharmova Annual General Meeting

Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.

Jubilant Pharmova Production Started

Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.

Jubilant Pharmova Annual General Meeting

Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.

Jubilant Pharmova Results Update

Jubilant Pharmova reported Q1 FY27 revenue of ₹2,229 Crore, reflecting 17% YoY growth. Net profit stood at ₹56 Crore amidst margin impacts.

Jubilant Pharmova Q1 FY27 Results: Net Profit ₹56.4 Cr, Down 45.0% YoY

Jubilant Pharmova Ltd reported revenue from operations of ₹2,229 Cr (+17.3% YoY) and net profit of ₹56.4 Cr (-45.0% YoY) for Q1 FY27.

Key figure

Net profit ₹56.4 Cr · -45.0% YoY